MTOR and acute lymphoblastic leukemia: In conclusion, PI3K/AKT/mTOR represents a major signaling pathway to be targeted in combination with NOTCH1 inhibitors, especially in T-ALL patients harboring PTEN inactivation where constitutive activation of PI3K/AKT signaling may lead to GSI resistance.